Department of Geriatrics, Xijing Hospital.
Department of Epidemiology, and.
J Clin Invest. 2024 Aug 6;134(18):e176507. doi: 10.1172/JCI176507.
BACKGROUNDFrailty significantly affects morbidity and mortality rates in the older population (age >65 years). Age-related degenerative diseases are influenced by the intestinal microbiota. However, limited research exists on alterations in the intestinal microbiota in frail older individuals, and the effectiveness of prebiotic intervention for treating frailty remains uncertain.OBJECTIVEWe sought to examine the biological characteristics of the intestinal microbiome in frail older individuals and assess changes in both frailty status and gut microbiota following intervention with a prebiotic blend consisting of inulin and oligofructose.METHODSThe study consisted of 3 components: an observational analysis with a sample size of 1,693, a cross-sectional analysis (n = 300), and a multicenter double-blind, randomized, placebo-controlled trial (n = 200). Body composition, commonly used scales, biochemical markers, intestinal microbiota, and metabolites were examined in 3 groups of older individuals (nonfrail, prefrail, and frail). Subsequently, changes in these indicators were reevaluated after a 3-month intervention using the prebiotic mixture for the prefrail and frail groups.RESULTSThe intervention utilizing a combination of prebiotics significantly improved frailty and renal function among the older population, leading to notable increases in protein levels, body fat percentage, walking speed, and grip strength. Additionally, it stimulated an elevation in gut probiotic count and induced alterations in microbial metabolite expression levels as well as corresponding metabolic pathways.CONCLUSIONSThe findings suggest a potential link between changes in the gut microbiota and frailty in older adults. Prebiotics have the potential to modify the gut microbiota and metabolome, resulting in improved frailty status and prevention of its occurrence.TRIAL REGISTRATIONClinicalTrials.gov NCT03995342.
虚弱显著影响老年人群(年龄>65 岁)的发病率和死亡率。与年龄相关的退行性疾病受肠道微生物群的影响。然而,关于虚弱老年人肠道微生物群的改变的研究有限,并且益生菌干预治疗虚弱的效果仍不确定。
我们旨在研究虚弱老年人肠道微生物组的生物学特征,并评估富含菊粉和低聚果糖的益生菌混合物干预后虚弱状态和肠道微生物群的变化。
该研究包括 3 个部分:观察性分析(样本量为 1693 例)、横断面分析(n=300)和多中心双盲、随机、安慰剂对照试验(n=200)。检查了 3 组老年人(非虚弱、虚弱前期和虚弱)的身体成分、常用量表、生化标志物、肠道微生物群和代谢物。随后,在 3 个月的干预期后,使用益生菌混合物重新评估这些指标在虚弱前期和虚弱组中的变化。
益生菌混合物的干预显著改善了老年人的虚弱和肾功能,导致蛋白质水平、体脂百分比、步行速度和握力显著增加。此外,它刺激了肠道益生菌计数的升高,并诱导了微生物代谢物表达水平以及相应代谢途径的改变。
这些发现表明肠道微生物群的变化与老年人的虚弱之间存在潜在联系。益生菌有可能改变肠道微生物群和代谢组,从而改善虚弱状态并预防其发生。
ClinicalTrials.gov NCT03995342。